Physician profile

Riley D Foreman

Cardiovascular Disease · Montrose, CO

NPI 1861424327

$677.82

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$132.90

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbott Laboratories $159.62 2019-2023 Jot Dx
Boston Scientific Corporation $140.99 2019-2022
E.R. Squibb & Sons, L.L.C. $125.68 2019-2023 Eliquis
Cook Medical LLC $74.11 2019
Astrazeneca Pharmaceuticals Lp $41.13 2019-2020
Medtronic, INC. $40.12 2021
Amgen INC. $35.36 2021
Medtronic Vascular, INC. $30.06 2020
Pfizer INC. $18.73 2023
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $12.02 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Riley D Foreman

$677.82

in general payments reported 2019-2025

Years
2019-2023
Top company
Abbott Laboratories

https://glasscript.com/doctor/729607/riley-d-foreman

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.